Skip to content

Study · Non-randomized trial · n = 54 · 2003

5 results

Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?

Leyh RG, Kofidis T, Kofidis T, Strüber M, Fischer S, Knobloch K, Wachsmann B, Hagl C, Simon AR, Haverich A

The Journal of thoracic and cardiovascular surgery1 Jun 2003Cited by 105 (Europe PMC)

PMID12830064 (opens in a new tab)DOI10.1016/s0022-5223(02)73284-4 (opens in a new tab)PepBankPUB-12830064
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    Among patients treated with methylene blue for refractory vasoplegia after bypass, three patients died during hospitalization.

    In plain wordsAmong patients receiving methylene blue for refractory vasoplegia after bypass, three died in hospital.

    Peptide
    Methylene blue
    Outcome
    Not applicableIn-hospital mortality
    Study

    n = 54

    Outcome group
    Mortality · Cardiovascular
    Studied dose
    2 mg/kg · intravenous · 20 minutesAs given in this study (human).

    Measurements

    In-hospital deaths
    3 patients
    single-arm methylene blue
    In-hospital mortality
    5.6%
    single-arm methylene blue

    Source sentences

    Summary
    Three patients (5.6%) died during the hospital stay.
    1 context sentence
    Summary · context
    A total of 54 patients with norepinephrine-refractory vasoplegia after cardiopulmonary bypass were treated with methylene blue (2 mg/kg) administered intravenously through a period of 20 minutes.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with refractory vasoplegia after bypass, systemic vascular resistance increased in 51 patients within 1 hour after methylene blue.

    In plain wordsIn patients with refractory vasoplegia after bypass, vascular resistance rose in 51 patients within 1 hour after methylene blue.

    Peptide
    Methylene blue
    Outcome
    IncreaseSystemic vascular resistance
    Study

    n = 54

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2 mg/kg · intravenous · 20 minutesAs given in this study (human).

    Measurements

    Patients with increase in systemic vascular resistance
    51 patients
    within 1 hour after methylene blue infusion

    Source sentences

    Summary
    A clinically relevant increase in systemic vascular resistance and a decrease in norepinephrine dosage were observed in 51 patients within 1 hour after methylene blue infusion.
    1 context sentence
    Summary · context
    A total of 54 patients with norepinephrine-refractory vasoplegia after cardiopulmonary bypass were treated with methylene blue (2 mg/kg) administered intravenously through a period of 20 minutes.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with refractory vasoplegia after bypass, norepinephrine dosage decreased in 51 patients within 1 hour after methylene blue.

    In plain wordsIn patients with refractory vasoplegia after bypass, norepinephrine doses fell in 51 patients within 1 hour after methylene blue.

    Peptide
    Methylene blue
    Outcome
    DecreaseNorepinephrine dosage
    Study

    n = 54

    Outcome group
    Intensive care and hospital outcomes · Cardiovascular
    Studied dose
    2 mg/kg · intravenous · 20 minutesAs given in this study (human).

    Measurements

    Patients with decrease in norepinephrine dosage
    51 patients
    within 1 hour after methylene blue infusion

    Source sentences

    Summary
    A clinically relevant increase in systemic vascular resistance and a decrease in norepinephrine dosage were observed in 51 patients within 1 hour after methylene blue infusion.
    1 context sentence
    Summary · context
    A total of 54 patients with norepinephrine-refractory vasoplegia after cardiopulmonary bypass were treated with methylene blue (2 mg/kg) administered intravenously through a period of 20 minutes.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with refractory vasoplegia after bypass, four patients had no response to methylene blue.

    In plain wordsIn patients with refractory vasoplegia after bypass, four patients did not respond to methylene blue.

    Peptide
    Methylene blue
    Outcome
    Not applicableNonresponse
    Study

    n = 54

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2 mg/kg · intravenous · 20 minutesAs given in this study (human).

    Measurements

    Patients with no response
    4 patients
    methylene blue
    Nonresponse
    7.4%
    methylene blue

    Source sentences

    Summary
    Four patients (7.4%) had no response to methylene blue.
    1 context sentence
    Summary · context
    A total of 54 patients with norepinephrine-refractory vasoplegia after cardiopulmonary bypass were treated with methylene blue (2 mg/kg) administered intravenously through a period of 20 minutes.
  5. 05HumanNon-randomized trialSafety outcome

    In patients with refractory vasoplegia after bypass, no adverse effects related to methylene blue were observed.

    In plain wordsIn patients with refractory vasoplegia after bypass, no adverse effects related to methylene blue were observed.

    Peptide
    Methylene blue
    Outcome
    Not applicableTreatment-related adverse effects
    Study

    n = 54

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    2 mg/kg · intravenous · 20 minutesAs given in this study (human).

    Source sentences

    Summary
    No adverse effects related to methylene blue were observed.
    1 context sentence
    Summary · context
    A total of 54 patients with norepinephrine-refractory vasoplegia after cardiopulmonary bypass were treated with methylene blue (2 mg/kg) administered intravenously through a period of 20 minutes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.